Actively Recruiting
Phase I Study Evaluating Safety and Dosing of HRS-7525 Tablets in Men With Advanced Prostate Cancer
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2026-09-24
320
Participants Needed
7
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and tolerability of HRS-7525 tablets in males with advanced prostate cancer. This Phase I clinical trial aims to identify the dose limiting toxicity, the maximum tolerated dose if possible, and the recommended Phase II dose of HRS-7525. The study focuses on patients with metastatic prostate adenocarcinoma who have a life expectancy of at least 12 weeks and good performance status. Participants will receive HRS-7525 tablets in a single-group study design. The trial includes a single-dose run-in period lasting 2 days followed by 21 days after the first administration to assess dose limiting toxicity. Safety follow-up will continue for about 13 months to evaluate the maximum tolerated dose and the recommended dose for further studies. Throughout the study, participants will be closely monitored with assessments related to safety and tolerability. Researchers will observe adverse events and collect data from the time of informed consent through the safety follow-up period. The total participant involvement may last up to approximately 13 months, during which the safety and pharmacokinetics of HRS-7525 will be evaluated.
CONDITIONS
Brief Title
A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
Research Team
J
Jianpo Lian
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here